Cargando...

AT-06 A PHASE II TRIAL OF TAMOXIFEN AND BORTEZOMIB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA

BACKGROUND: Preclinical studies indicated that inhibition of NF-kB with bortezemib markedly enhance tamoxifen-mediated glioma apoptosis. A potentially synergistic cytotoxic effect of the combination may benefit patients with malignant gliomas. METHODS: We conducted single institution phase II trial...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Aregawi, Dawit, Kreisl, Teri N., Innis, Ellen, Fine, Howard A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2014
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217841/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!